Cargando…
Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain
OBJECTIVE: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. DESIGN: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low back pain (CLBP). SETTING: Conducted in the U...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530570/ https://www.ncbi.nlm.nih.gov/pubmed/32150255 http://dx.doi.org/10.1093/pm/pnz326 |
_version_ | 1783589593654755328 |
---|---|
author | Henningfield, Jack E Gudin, Jeffrey Rauck, Richard Gimbel, Joseph Tagliaferri, Mary Doberstein, Stephen K Di Fonzo, Carlo Lu, Lin Katz, Nathaniel Siddhanti, Suresh Schnoll, Sidney |
author_facet | Henningfield, Jack E Gudin, Jeffrey Rauck, Richard Gimbel, Joseph Tagliaferri, Mary Doberstein, Stephen K Di Fonzo, Carlo Lu, Lin Katz, Nathaniel Siddhanti, Suresh Schnoll, Sidney |
author_sort | Henningfield, Jack E |
collection | PubMed |
description | OBJECTIVE: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. DESIGN: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low back pain (CLBP). SETTING: Conducted in the United States at multiple sites. METHODS: SUMMIT-07 was comprised of five periods: screening; NKTR-181 open-label titration (100 to 400 mg twice daily); 12-week randomized, double-blind study drug (NKTR-181 or placebo); one-week study drug taper; and two-week safety follow-up. Permitted rescue medication included hydrocodone 5 mg/acetaminophen 300 mg (two tablets daily) for two weeks after randomization, then acetaminophen 1.0 gm daily for the remainder of the trial. Signs and symptoms of drug withdrawal were evaluated using the Clinical Opiate Withdrawal Scale (COWS); Subjective Opiate Withdrawal Scale (SOWS); Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS); and withdrawal-related adverse events. RESULTS: Of 1,190 patients entering titration, one patient had moderate withdrawal (COWS score 13/48 maximum) three days after discontinuing NKTR-181. Of 610 patients randomized (N = 309, NKTR-181; N = 301, placebo), no COWS scores indicating withdrawal at a moderate level or greater (i.e., score ≥13) were observed at any time point. At day 8 after randomization, week 12, and the end of tapering, COWS scores indicating mild withdrawal (<13) were observed in seven (2.4%), one (0.4%), and one (0.5%) placebo patients, respectively, and three (1.0%), one (0.4%), and five (2.3%) NKTR-181 patients, respectively. Mean SOWS scores in both arms were ≤2.8 of 64 possible points at all time points. During the randomized period, of 35 events identified by MADDERS, adjudicators identified 20 possible “withdrawal” events (9 [2.9%] NKTR-181 and 11 [3.7%] placebo). CONCLUSIONS: NKTR-181 exhibited a low rate and severity of opioid withdrawal in SUMMIT-07 patients with CLBP. |
format | Online Article Text |
id | pubmed-7530570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75305702020-10-07 Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain Henningfield, Jack E Gudin, Jeffrey Rauck, Richard Gimbel, Joseph Tagliaferri, Mary Doberstein, Stephen K Di Fonzo, Carlo Lu, Lin Katz, Nathaniel Siddhanti, Suresh Schnoll, Sidney Pain Med Opioids & Substance Use Disorders Section OBJECTIVE: To evaluate the SUMMIT-07 trial opioid withdrawal results of NKTR-181 (oxycodegol), a new molecular entity mu-opioid receptor agonist. DESIGN: Phase 3, enriched-enrollment, double-blind, randomized-withdrawal study in patients with chronic low back pain (CLBP). SETTING: Conducted in the United States at multiple sites. METHODS: SUMMIT-07 was comprised of five periods: screening; NKTR-181 open-label titration (100 to 400 mg twice daily); 12-week randomized, double-blind study drug (NKTR-181 or placebo); one-week study drug taper; and two-week safety follow-up. Permitted rescue medication included hydrocodone 5 mg/acetaminophen 300 mg (two tablets daily) for two weeks after randomization, then acetaminophen 1.0 gm daily for the remainder of the trial. Signs and symptoms of drug withdrawal were evaluated using the Clinical Opiate Withdrawal Scale (COWS); Subjective Opiate Withdrawal Scale (SOWS); Misuse, Abuse, and Diversion Drug Event Reporting System (MADDERS); and withdrawal-related adverse events. RESULTS: Of 1,190 patients entering titration, one patient had moderate withdrawal (COWS score 13/48 maximum) three days after discontinuing NKTR-181. Of 610 patients randomized (N = 309, NKTR-181; N = 301, placebo), no COWS scores indicating withdrawal at a moderate level or greater (i.e., score ≥13) were observed at any time point. At day 8 after randomization, week 12, and the end of tapering, COWS scores indicating mild withdrawal (<13) were observed in seven (2.4%), one (0.4%), and one (0.5%) placebo patients, respectively, and three (1.0%), one (0.4%), and five (2.3%) NKTR-181 patients, respectively. Mean SOWS scores in both arms were ≤2.8 of 64 possible points at all time points. During the randomized period, of 35 events identified by MADDERS, adjudicators identified 20 possible “withdrawal” events (9 [2.9%] NKTR-181 and 11 [3.7%] placebo). CONCLUSIONS: NKTR-181 exhibited a low rate and severity of opioid withdrawal in SUMMIT-07 patients with CLBP. Oxford University Press 2020-08 2020-03-09 /pmc/articles/PMC7530570/ /pubmed/32150255 http://dx.doi.org/10.1093/pm/pnz326 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the American Academy of Pain Medicine. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License(http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Opioids & Substance Use Disorders Section Henningfield, Jack E Gudin, Jeffrey Rauck, Richard Gimbel, Joseph Tagliaferri, Mary Doberstein, Stephen K Di Fonzo, Carlo Lu, Lin Katz, Nathaniel Siddhanti, Suresh Schnoll, Sidney Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain |
title | Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain |
title_full | Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain |
title_fullStr | Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain |
title_full_unstemmed | Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain |
title_short | Measuring Opioid Withdrawal in a Phase 3 Study of a New Analgesic, NKTR-181 (Oxycodegol), in Patients with Moderate to Severe Chronic Low Back Pain |
title_sort | measuring opioid withdrawal in a phase 3 study of a new analgesic, nktr-181 (oxycodegol), in patients with moderate to severe chronic low back pain |
topic | Opioids & Substance Use Disorders Section |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530570/ https://www.ncbi.nlm.nih.gov/pubmed/32150255 http://dx.doi.org/10.1093/pm/pnz326 |
work_keys_str_mv | AT henningfieldjacke measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT gudinjeffrey measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT rauckrichard measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT gimbeljoseph measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT tagliaferrimary measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT dobersteinstephenk measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT difonzocarlo measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT lulin measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT katznathaniel measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT siddhantisuresh measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain AT schnollsidney measuringopioidwithdrawalinaphase3studyofanewanalgesicnktr181oxycodegolinpatientswithmoderatetoseverechroniclowbackpain |